On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
nSEPIA aims to bring structure to an area long dominated by subjectivity
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Subscribe To Our Newsletter & Stay Updated
